WallStSmart

Milestone Scientific (MLSS)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 62097% more annual revenue ($5.54B vs $8.90M). RMD leads profitability with a 27.4% profit margin vs -51.3%. RMD earns a higher WallStSmart Score of 73/100 (B).

MLSS

Avoid

16

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: -24.40

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.0Value: 4.7Quality: 9.5
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MLSSUndervalued (+72.0%)

Margin of Safety

+72.0%

Fair Value

$0.95

Current Price

$0.39

$0.56 discount

UndervaluedFair: $0.95Overvalued
RMDSignificantly Overvalued (-26.9%)

Margin of Safety

-26.9%

Fair Value

$204.63

Current Price

$196.04

$8.59 premium

UndervaluedFair: $204.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MLSS0 strengths · Avg: 0/10

No standout strengths identified

RMD5 strengths · Avg: 9.4/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.4%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

Areas to Watch

MLSS4 concerns · Avg: 3.5/10
Price/BookValuation
13.0x4/10

Trading at 13.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$33.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : MLSS

MLSS has a balanced fundamental profile.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : MLSS

The primary concerns for MLSS are Price/Book, EPS Growth, Market Cap.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

MLSS profiles as a turnaround stock while RMD is a mature play — different risk/reward profiles.

MLSS carries more volatility with a beta of 0.97 — expect wider price swings.

RMD is growing revenue faster at 10.8% — sustainability is the question.

RMD generates stronger free cash flow (520M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (73/100 vs 16/100), backed by strong 27.4% margins and 10.8% revenue growth. MLSS offers better value entry with a 72.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Milestone Scientific

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Milestone Scientific, Inc. develops computer-controlled anesthetic delivery devices for the medical and dental markets in the United States, China, and internationally. The company is headquartered in Livingston, New Jersey.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?